Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VOR Vor Biopharma Inc.

Not Yet Opened 06-25 16:00:00 EDT

1.24

+0.00

0.00%

盘后1.24

+0.000.00%

18:38 EDT

High1.24	Low1.20	Vol716.59K
Open1.22	D1 Closing1.24	Amplitude3.23%
Mkt Cap84.64M	Tradable Cap39.61M	Total Shares68.26M
T/O884.35K	T/O Rate2.24%	Tradable Shares31.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VOR","market":"US","secType":"STK","nameCN":"Vor Biopharma Inc.","latestPrice":1.24,"timestamp":1719345600000,"preClose":1.24,"halted":0,"volume":716593,"hourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.24,"latestTime":"18:38 EDT","volume":321839,"amount":399081.01,"timestamp":1719355110671},"delay":0,"floatShares":31945841,"shares":68259602,"eps":-1.777734,"marketStatus":"Not Yet Opened","change":0,"latestTime":"06-25 16:00:00 EDT","open":1.22,"high":1.24,"low":1.2,"amount":884350.5026499,"amplitude":0.032258,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.777734,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1719388800000},"marketStatusCode":0,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":1.24,"preHourTrading":{"tag":"盘前","latestPrice":1.23,"preClose":1.24,"latestTime":"09:24 EDT","volume":310,"amount":378.00001899999995,"timestamp":1719321872787},"postHourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.24,"latestTime":"18:38 EDT","volume":321839,"amount":399081.01,"timestamp":1719355110671},"volumeRatio":2.896102,"impliedVol":1.107,"impliedVolPercentile":0.5675},"requestUrl":"/m/hq/s/VOR","defaultTab":"news","newsList":[{"id":"2434955538","title":"Silvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2434955538","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434955538?lang=en_us&edition=fundamental","pubTime":"2024-05-11 03:35","pubTimestamp":1715369723,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JM...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/silvan-tuerkcan-reaffirms-buy-rating-for-vor-biopharma-citing-clinical-progress-and-expanding-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/silvan-tuerkcan-reaffirms-buy-rating-for-vor-biopharma-citing-clinical-progress-and-expanding-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU2065732104.USD","BK4139","PRGS","VOR"],"gpt_icon":0},{"id":"2434856971","title":"Vor Biopharma (VOR) Receives a Buy from Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2434856971","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434856971?lang=en_us&edition=fundamental","pubTime":"2024-05-10 20:46","pubTimestamp":1715345206,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $11.00. The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vor-biopharma-vor-receives-a-buy-from-wedbush?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vor-biopharma-vor-receives-a-buy-from-wedbush?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2434376078","title":"Vor Biopharma GAAP EPS of $0.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2434376078","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434376078?lang=en_us&edition=fundamental","pubTime":"2024-05-10 19:20","pubTimestamp":1715340002,"startTime":"0","endTime":"0","summary":"Vor Biopharma press release  (NASDAQ:VOR): Q1  GAAP EPS of $0.45.\nCash, cash equivalents and marketable securities were $107.5 million as of March 31, 2024,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4104473-vor-biopharma-gaap-eps-of-0_45","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139",".IXIC","TQQQ","QLD","QQQ","VOR","MNQmain","QID","NQmain","SQQQ","PSQ"],"gpt_icon":0},{"id":"2434839291","title":"Promising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2434839291","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434839291?lang=en_us&edition=fundamental","pubTime":"2024-05-10 18:17","pubTimestamp":1715336236,"startTime":"0","endTime":"0","summary":"Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Vor Biopharma (VOR – Research Report), retaining the price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-trials-and-stable-financial-outlook-bolster-buy-rating-for-vor-biopharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-trials-and-stable-financial-outlook-bolster-buy-rating-for-vor-biopharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2434047195","title":"Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2434047195","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434047195?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:05","pubTimestamp":1715285100,"startTime":"0","endTime":"0","summary":"On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024. Trem-cel trial expanded to include patients with myelodysplastic syndromes ; Mylotargdosing has advanced to the third cohort. CAMBRIDGE, Mass., May 09, 2024  -- Vor Bio , a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update.“We are pleased with the strong enthusiasm from investigators to enroll patients in both of our clinical trials and are encouraged by the number of VCAR33ALLO CAR-T trial sites that are now active, many of which overlap with our trem-cel sites,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We are fully focused on execution of these clinical trials and are looking forward to our next substantive data update.”Accomplished oncology and cancer immunotherapy R&D executive joins Board As previously announced, the Company has appointed Fouad Namouni, M.D.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-bio-reports-first-quarter-200500626.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VOR","BK4139"],"gpt_icon":0},{"id":"2433056612","title":"Vor Biopharma Inc    expected to post a loss of 38 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2433056612","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433056612?lang=en_us&edition=fundamental","pubTime":"2024-05-07 20:20","pubTimestamp":1715084426,"startTime":"0","endTime":"0","summary":"* Vor Biopharma Inc     is expected to show no change in quarterly revenue when it reports  results on May 9 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estimate for V","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOR"],"gpt_icon":0},{"id":"2432550009","title":"Vor Biopharma Welcomes Oncology Expert to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2432550009","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432550009?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:27","pubTimestamp":1714681623,"startTime":"0","endTime":"0","summary":"Vor Biopharma (VOR) has shared an update. Vor Biopharma Inc. has expanded its Board of Directors with the appointment of Fouad Namouni, M.D., as an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-welcomes-oncology-expert-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vor-biopharma-welcomes-oncology-expert-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2432830956","title":"Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2432830956","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432830956?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:01","pubTimestamp":1714680060,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May 02, 2024  -- Vor Bio , a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio's Board.\"We are thrilled to welcome Dr. Namouni to Vor Bio's Board of Directors,\" said Dr. Robert Ang, President and CEO of Vor Bio. \"His deep oncology development experience will be invaluable as Vor Bio navigates toward late phase trials and beyond.\" Matthew R. Patterson, Chairman of Vor Bio, added, “Dr. Namouni’s decades of industry experience in both pharmaceutical and biotechnology research and development complements and strengthens the diverse perspectives on Vor’s Board and I look forward to working closely with him.”About Vor BioVor Bio is a clinical-stage cell and genome engineering company that aims to change the s","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-bio-appoints-accomplished-oncology-200100355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2427536357","title":"Buy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2427536357","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2427536357?lang=en_us&edition=fundamental","pubTime":"2024-04-13 01:25","pubTimestamp":1712942727,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh maintained a Buy rating on Vor Biopharma (VOR – Research Report) today and set a price target of $18.00. Justin W...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-vor-biopharma-on-clinical-progress-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-vor-biopharma-on-clinical-progress-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VOR","PRGS","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2424319439","title":"Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2424319439","media":"Zacks","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424319439?lang=en_us&edition=fundamental","pubTime":"2024-04-04 20:32","pubTimestamp":1712233920,"startTime":"0","endTime":"0","summary":"One stock that might be an intriguing choice for investors right now is Vor Biopharma Inc. VOR. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 73 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.Meanwhile, Vor Biopharma is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-shouldnt-bet-against-vor-123200648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VOR"],"gpt_icon":0},{"id":"2423121881","title":"PLAB, SMTC and WOOF are among after hour movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2423121881","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2423121881?lang=en_us&edition=fundamental","pubTime":"2024-03-29 04:52","pubTimestamp":1711659133,"startTime":"0","endTime":"0","summary":"Gainers:Semtech Corporation (SMTC) +10%.Zentalis Pharmaceuticals (ZNTL) +9%.Sagimet Biosciences (SGMT) +5%.Photronics (PLAB) +5%.James River Group Holdings (JRVR) +4%.Losers:AnaptysBio (ANAB) -7%.Vor Biopharma (VOR) -6%.Argo Blockchain (ARBK) -5%.Petco Health and Wellness Company (WOOF) -4%.Apellis Pharmaceuticals (APLS) -4%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085196-plab-smtc-and-woof-are-among-after-hour-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4505","WOOF","LU1093756168.USD","BK4585","ANAB","ZNTL","ARBK","BK4139","VOR","BK4023","JRVR","BK4107","SGMT","APLS","SMTC","BK4595","BK4588","LU1093756325.SGD","BK4141","BK4147","PLAB","BK4200"],"gpt_icon":0},{"id":"2423144773","title":"The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness","url":"https://stock-news.laohu8.com/highlight/detail?id=2423144773","media":"InvestorPlace","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2423144773?lang=en_us&edition=fundamental","pubTime":"2024-03-29 02:28","pubTimestamp":1711650530,"startTime":"0","endTime":"0","summary":"In most cases, investors should stay away from penny stocks. They’re wild, they’re unpredictable and they tend to lose their stakeholders money more so than…","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/03/the-penny-stock-a-list-7-high-profile-companies-on-the-verge-of-greatness/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["QLD","QQQ","PRTS","QID","BK4214","PWFL","BK4122","BK4139","BK4020","LTRX","MNQmain","TQQQ","VOR","PSQ","BK4157","NQmain","ACET","ARBE","KRMD","SQQQ",".IXIC","BK4082"],"gpt_icon":0},{"id":"2422690762","title":"Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Inotiv (NOTV) and Vericel (VCEL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422690762","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422690762?lang=en_us&edition=fundamental","pubTime":"2024-03-26 20:50","pubTimestamp":1711457407,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vor Biopharma (VOR – Research Report), Inotiv (NOTV ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-inotiv-notv-and-vericel-vcel?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vor-biopharma-vor-inotiv-notv-and-vericel-vcel?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4121","HCSG","NOTV","BK4137","VCEL","VOR"],"gpt_icon":0},{"id":"2422756686","title":"Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422756686","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422756686?lang=en_us&edition=fundamental","pubTime":"2024-03-26 10:05","pubTimestamp":1711418728,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Vor Biopharma (VOR – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VOR","BK4139","BK4127","SF"],"gpt_icon":0},{"id":"2422158536","title":"Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422158536","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422158536?lang=en_us&edition=fundamental","pubTime":"2024-03-25 09:50","pubTimestamp":1711331450,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immatics (IMTX – Research Report), Vor Biopharma (VO...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immatics-imtx-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immatics-imtx-vor-biopharma-vor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4137","VOR","IMTX","HCSG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vorbio.com","stockEarnings":[{"period":"1week","weight":0.0333},{"period":"1month","weight":-0.2026},{"period":"3month","weight":-0.4389},{"period":"6month","weight":-0.5231},{"period":"1year","weight":-0.6492},{"period":"ytd","weight":-0.4489}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":0.0291},{"period":"3month","weight":0.0414},{"period":"6month","weight":0.1429},{"period":"1year","weight":0.2628},{"period":"ytd","weight":0.1463}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.158438},{"month":2,"riseRate":0.666667,"avgChangeRate":0.051123},{"month":3,"riseRate":0.25,"avgChangeRate":-0.094474},{"month":4,"riseRate":0,"avgChangeRate":-0.211155},{"month":5,"riseRate":0.25,"avgChangeRate":-0.168862},{"month":6,"riseRate":0.25,"avgChangeRate":-0.089906},{"month":7,"riseRate":0,"avgChangeRate":-0.141258},{"month":8,"riseRate":0.666667,"avgChangeRate":0.037979},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.102926},{"month":10,"riseRate":0.666667,"avgChangeRate":0.02498},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0997},{"month":12,"riseRate":1,"avgChangeRate":0.222933}],"exchange":"NASDAQ","name":"Vor Biopharma Inc.","nameEN":"Vor Biopharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vor Biopharma Inc.,VOR,Vor Biopharma Inc.股票,Vor Biopharma Inc.股票老虎,Vor Biopharma Inc.股票老虎国际,Vor Biopharma Inc.行情,Vor Biopharma Inc.股票行情,Vor Biopharma Inc.股价,Vor Biopharma Inc.股市,Vor Biopharma Inc.股票价格,Vor Biopharma Inc.股票交易,Vor Biopharma Inc.股票购买,Vor Biopharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vor Biopharma Inc.(VOR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vor Biopharma Inc.(VOR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction